Detail akcie Marinomed Biot Br online

Business Summary: Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH, is an Austria-based biopharmaceutical company. The Company operates in two segments such as Virology and Immunology. It develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose, platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients, this technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Marinomed Biotech AG revenues increased from EUR2.5M to EUR7.2M. Net income totaled EUR20.7M vs. loss of EUR10.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Financial expenses decrease of 96% to EUR270K (expense), Personnel Expenses decrease of 19% to EUR2.2M (expense).